MapLight Therapeutics, Inc. — Form S-1
Filed September 9, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 24/100
What the filing says
MapLight Therapeutics filed an S-1 registration statement on September 9, 2026, to register 13,181,055 shares for resale by investors who participated in a private placement closed August 14, 2026. The company issued 9,197,887 common shares at $11.38/share and pre-funded warrants for 3,983,168 shares at $11.3799/share, generating ~$150M gross proceeds. The company receives no proceeds from these resales; the registration satisfies contractual registration rights obligations to the private placement investors.
Why this rating
S-1 resale registrations are routine administrative filings. Shares already issued and proceeds already received in August 2026. Resale registration does not change capital structure or raise new funds. Stock price pressure from future resales is speculative risk, not a current material event.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.